720706-20-7

Usage

InChI:InChI=1/C6H13NO2/c7-6(5-8)1-3-9-4-2-6/h8H,1-5,7H2

Upstream product

• 217299-03-1 4-aminotetrahydro-2H-pyran-4-carboxylic acid hydrochloride 
• 50289-12-8 4-amino-tetrahydro-2H-pyran-4-carbonitrile 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 39124-20-4 4-aminotetrahydro-2H-pyran-4-carboxylic acid 
• 184698-41-7 4-aminotetrahydropyran-4-carboxylicacid methyl ester 

Downstream Products

• 1029716-09-3 tert-butyl (4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)carbamate 
• 1350473-46-9 2-cyclopropyl-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (4-hydroxymethyltetrahydropyran-4-yl)amide 
• 1207754-85-5 1-[(4-methylphenyl)sulfonyl]-6-oxa-1-azaspiro[2.5]octane 
• 1378810-18-4 2-isopropyl-1-aza-3,8-dioxaspiro[4.5]decane 

Relevant academic research and scientific papers

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE

Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.

Design and Synthesis of Fsp3-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening

The exploration of innovative chemical space is a critical step in the early phases of drug discovery. Bis-spirocyclic frameworks occur in natural products and other biologically relevant metabolites and show attractive features, such as molecular compactness, structural complexity, and three-dimensional character. A concise approach to the synthesis of bis-spirocyclic-based compound libraries starting from readily available commercial reagents and robust chemical transformations has been developed. A number of novel bis-spirocyclic scaffold examples, as implemented in the European Lead Factory project, is presented.

Quinazoline analogs as receptor tyrosine kinase inhibitors

This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.